Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of SAR443820 in adult participants with amyotrophic lateral sclerosis, followed by an open-label extension
Details
Age
Adult
Eligibility
Age 18-80 Diagnosis: ALS Onset of ALS symptoms less than 24 months ago Able to swallow pills
Type of Study
Treatment
Locations
Outpatient CTRC
University of Colorado Hospital
Principal Investigator
Thomas Ragole, MD
Study ID
Protocol Number: 22-0037
More information available at ClinicalTrials.gov: NCT05237284
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers